Literature DB >> 28473642

Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.

Christina J Schier1, William D Marks1, Jason J Paris1, Aaron J Barbour2, Virginia D McLane1, William F Maragos3,4, A Rory McQuiston2, Pamela E Knapp1,2,5, Kurt F Hauser6,2,5.   

Abstract

Despite marked regional differences in HIV susceptibility within the CNS, there has been surprisingly little exploration into the differential vulnerability among neuron types and the circuits they underlie. The dorsal striatum is especially susceptible, harboring high viral loads and displaying marked neuropathology, with motor impairment a frequent manifestation of chronic infection. However, little is known about the response of individual striatal neuron types to HIV or how this disrupts function. Therefore, we investigated the morphological and electrophysiological effects of HIV-1 trans-activator of transcription (Tat) in dopamine subtype 1 (D1) and dopamine subtype 2 (D2) receptor-expressing striatal medium spiny neurons (MSNs) by breeding transgenic Tat-expressing mice to Drd1a-tdTomato- or Drd2-eGFP-reporter mice. An additional goal was to examine neuronal vulnerability early during the degenerative process to gain insight into key events underlying the neuropathogenesis. In D2 MSNs, exposure to HIV-1 Tat reduced dendritic spine density significantly, increased dendritic damage (characterized by swellings/varicosities), and dysregulated neuronal excitability (decreased firing at 200-300 pA and increased firing rates at 450 pA), whereas insignificant morphologic and electrophysiological consequences were observed in Tat-exposed D1 MSNs. These changes were concomitant with an increased anxiety-like behavioral profile (lower latencies to enter a dark chamber in a light-dark transition task, a greater frequency of light-dark transitions, and reduced rearing time in an open field), whereas locomotor behavior was unaffected by 2 weeks of Tat induction. Our findings suggest that D2 MSNs and a specific subset of neural circuits within the dorsal striatum are preferentially vulnerable to HIV-1.SIGNIFICANCE STATEMENT Despite combination antiretroviral therapy (cART), neurocognitive disorders afflict 30-50% of HIV-infected individuals and synaptodendritic injury remains evident in specific brain regions such as the dorsal striatum. A possible explanation for the sustained neuronal injury is that the neurotoxic HIV-1 regulatory protein trans-activator of transcription (Tat) continues to be expressed in virally suppressed patients on cART. Using inducible Tat-expressing transgenic mice, we found that dopamine subtype 2 (D2) receptor-expressing medium spiny neurons (MSNs) are selectively vulnerable to Tat exposure compared with D1 receptor-expressing MSNs. This includes Tat-induced reductions in D2 MSN dendritic spine density, increased dendritic damage, and disruptions in neuronal excitability, which coincide with elevated anxiety-like behavior. These data suggest that D2 MSNs and specific circuits within the basal ganglia are preferentially vulnerable to HIV-1.
Copyright © 2017 the authors 0270-6474/17/375759-12$15.00/0.

Entities:  

Keywords:  Drd1a-tdTomato-expressing neurons; Drd2-eGFP-expressing neurons; basal ganglia; striatal indirect pathway; synaptic dysfunction; whole-cell patch-clamp physiology

Mesh:

Substances:

Year:  2017        PMID: 28473642      PMCID: PMC5469310          DOI: 10.1523/JNEUROSCI.0622-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  100 in total

Review 1.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

2.  Modulation by dopamine D1-like receptors of synaptic transmission and NMDA receptors in rat nucleus accumbens is attenuated by the protein kinase C inhibitor Ro 32-0432.

Authors:  K Chergui; M G Lacey
Journal:  Neuropharmacology       Date:  1999-02       Impact factor: 5.250

3.  Increased Sensitivity to Cocaine Self-Administration in HIV-1 Transgenic Rats is Associated with Changes in Striatal Dopamine Transporter Binding.

Authors:  Scot McIntosh; Tammy Sexton; Lindsey P Pattison; Steven R Childers; Scott E Hemby
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-10       Impact factor: 4.147

4.  Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons.

Authors:  Sylvia Fitting; Ruqiang Xu; Cecilia Bull; Shreya K Buch; Nazira El-Hage; Avindra Nath; Pamela E Knapp; Kurt F Hauser
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

5.  HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells.

Authors:  G Zauli; P Secchiero; L Rodella; D Gibellini; P Mirandola; M Mazzoni; D Milani; D R Dowd; S Capitani; M Vitale
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

6.  Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.

Authors:  S J Augood; R L Faull; P C Emson
Journal:  Ann Neurol       Date:  1997-08       Impact factor: 10.422

Review 7.  HIV-related movement disorders: epidemiology, pathogenesis and management.

Authors:  Francisco Cardoso
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes.

Authors:  Jun Zhu; Charles F Mactutus; David R Wallace; Rosemarie M Booze
Journal:  J Pharmacol Exp Ther       Date:  2009-03-26       Impact factor: 4.030

9.  HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes.

Authors:  Eliseo A Eugenin; Jessie E King; Avindra Nath; Tina M Calderon; R Suzanne Zukin; Michael V L Bennett; Joan W Berman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

10.  Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice.

Authors:  Sylvia Fitting; David L Stevens; Fayez A Khan; Krista L Scoggins; Rachel M Enga; Patrick M Beardsley; Pamela E Knapp; William L Dewey; Kurt F Hauser
Journal:  J Pharmacol Exp Ther       Date:  2015-11-05       Impact factor: 4.030

View more
  27 in total

Review 1.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

2.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

4.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

5.  HIV and opiates dysregulate K+- Cl- cotransporter 2 (KCC2) to cause GABAergic dysfunction in primary human neurons and Tat-transgenic mice.

Authors:  Aaron J Barbour; Kurt F Hauser; A Rory McQuiston; Pamela E Knapp
Journal:  Neurobiol Dis       Date:  2020-04-25       Impact factor: 5.996

6.  Age-Related Decrease in Tyrosine Hydroxylase Immunoreactivity in the Substantia Nigra and Region-Specific Changes in Microglia Morphology in HIV-1 Tg Rats.

Authors:  David R Goulding; Andrew Kraft; Peter R Mouton; Christopher A McPherson; Valeria Avdoshina; Italo Mocchetti; G Jean Harry
Journal:  Neurotox Res       Date:  2019-07-08       Impact factor: 3.911

7.  Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.

Authors:  Jared Lee; Ji-Young Lee; Christina S Meade; Michael Cohn; Antonio Chahine; Samantha E Dilworth; Jessica F Magidson; Hetta Gouse; Dietmar Fuchs; Adam W Carrico
Journal:  J Neurovirol       Date:  2020-07-29       Impact factor: 2.643

8.  HIV Tat causes synapse loss in a mouse model of HIV-associated neurocognitive disorder that is independent of the classical complement cascade component C1q.

Authors:  Jennetta W Hammond; Wen Q Qiu; Daniel F Marker; Jeffrey M Chamberlain; Will Greaves-Tunnell; Matthew J Bellizzi; Shao-Ming Lu; Harris A Gelbard
Journal:  Glia       Date:  2018-10-16       Impact factor: 7.452

9.  Electrophysiological properties of medium spiny neurons in the nucleus accumbens core of prepubertal male and female Drd1a-tdTomato line 6 BAC transgenic mice.

Authors:  Jinyan Cao; David M Dorris; John Meitzen
Journal:  J Neurophysiol       Date:  2018-07-05       Impact factor: 2.714

10.  Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease.

Authors:  Eva M Müller-Oehring; Rosemary Fama; Taylor F Levine; Cheshire Hardcastle; Ryan Goodcase; Talora Martin; Varsha Prabhakar; Helen M Brontë-Stewart; Kathleen L Poston; Edith V Sullivan; Tilman Schulte
Journal:  J Neuropsychol       Date:  2020-10-08       Impact factor: 2.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.